Payment overview · 2025
General Payments
$6,401.81
77 reported records · 17 companies
Healthcare provider profile · identity verified
Loren E Mccoy, MD FACP
Allopathic & Osteopathic Physicians|Internal Medicine · MUSCLE SHOALS, AL · NPI 1447312822
Verified facts
What the public records show
CMS Open Payments records show Loren E Mccoy, MD FACP received $6,401.81 in general payments during 2025 across 77 reported records.
ABBVIE INC. accounted for 50.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Trintellix, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,236.87 | 50.6% | 23 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,296.27 | 35.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.21 | 2.6% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $157.68 | 2.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.25 | 2.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.67 | 1.6% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.36 | 0.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.07 | 0.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.60 | 0.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.18 | 0.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.03 | 0.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.00 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.86 | 0.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.72 | 0.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.14 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.86 | 0.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.04 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,333.75 | 7 |
| Food and Beverage | $1,068.06 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $3,157.40 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $2,322.08 | 14 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $2,296.27 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.42 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $114.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.43 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.43 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.82 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.82 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.82 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.80 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.36 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.07 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.79 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.24 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 154 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 320 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
312 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
320 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
280 | 50 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 939 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 927 | 204 |
| Metformin Hcl Er | Metformin Hcl | 885 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 876 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 204 |
| Pantoprazole Sodium | Pantoprazole Sodium | 775 | 202 |
| Omeprazole | Omeprazole | 678 | 156 |
| Gabapentin | Gabapentin | 661 | 153 |
| Duloxetine Hcl | Duloxetine Hcl | 591 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 550 | 160 |
| Meloxicam | Meloxicam | 542 | 128 |
| Potassium Chloride | Potassium Chloride | 513 | 131 |
| Escitalopram Oxalate | Escitalopram Oxalate | 460 | 116 |
| Alprazolam | Alprazolam | 432 | 81 |
| Losartan Potassium | Losartan Potassium | 425 | 100 |
| Clonazepam | Clonazepam | 411 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 376 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 338 | 80 |
| Tramadol Hcl | Tramadol Hcl | 333 | 78 |
| Celecoxib | Celecoxib | 325 | 88 |
| Ozempic | Semaglutide | 320 | 52 |
| Mounjaro | Tirzepatide | 312 | 48 |
| Spironolactone | Spironolactone | 310 | 84 |
| Trazodone Hcl | Trazodone Hcl | 291 | 64 |
| Eliquis | Apixaban | 280 | 50 |
| Lisinopril | Lisinopril | 280 | 75 |
| Allopurinol | Allopurinol | 255 | 66 |
| Irbesartan | Irbesartan | 250 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 247 | 42 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 241 | 62 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 232 | 47 |
| Montelukast Sodium | Montelukast Sodium | 231 | 55 |
| Furosemide | Furosemide | 224 | 55 |
| Famotidine | Famotidine | 215 | 57 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 208 | 49 |
| Donepezil Hcl | Donepezil Hcl | 196 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 196 | 47 |
| Pregabalin | Pregabalin | 194 | 40 |
| Lorazepam | Lorazepam | 192 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 190 | 53 |
| Jardiance | Empagliflozin | 189 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 59 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 186 | 41 |
| Carvedilol | Carvedilol | 183 | 52 |
| Metformin Hcl | Metformin Hcl | 178 | 52 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 174 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 167 | 52 |
| Torsemide | Torsemide | 155 | 44 |
| Farxiga | Dapagliflozin Propanediol | 154 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 25 |
| Sertraline Hcl | Sertraline Hcl | 153 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 45 |
| Bupropion Xl | Bupropion Hcl | 148 | 41 |
| Cefdinir | Cefdinir | 140 | 121 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 131 | 27 |
| Xarelto | Rivaroxaban | 130 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 23 |
| Estradiol | Estradiol | 127 | 34 |
| Temazepam | Temazepam | 127 | 33 |
| Glimepiride | Glimepiride | 118 | 24 |
| Trulicity | Dulaglutide | 116 | 21 |
| Fenofibrate | Fenofibrate,micronized | 115 | 28 |
| Buspirone Hcl | Buspirone Hcl | 106 | 31 |
| Simvastatin | Simvastatin | 106 | 26 |
| Fluconazole | Fluconazole | 102 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 96 | 18 |
| Methocarbamol | Methocarbamol | 96 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 26 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 95 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 19 |
| Meclizine Hcl | Meclizine Hcl | 93 | 33 |
| Vascepa | Icosapent Ethyl | 93 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 89 | 21 |
| Mirtazapine | Mirtazapine | 89 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 85 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 39 |
| Azithromycin | Azithromycin | 80 | 71 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 78 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 16 |
| Diazepam | Diazepam | 71 | suppressed |
| Synthroid | Levothyroxine Sodium | 70 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 67 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 67 | 13 |
| Topiramate | Topiramate | 67 | 15 |
| Finasteride | Finasteride | 65 | 13 |
| Ibuprofen | Ibuprofen | 65 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 54 |
| Linzess | Linaclotide | 63 | 15 |
| Ondansetron Odt | Ondansetron | 62 | 32 |
| Ramipril | Ramipril | 61 | 17 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Lansoprazole | Lansoprazole | 55 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 45 | 11 |
| Trulance | Plecanatide | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 44 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 13 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | 11 |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 42 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 35 |
| Glyxambi | Empagliflozin/Linagliptin | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Fluocinonide | Fluocinonide | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 31 |
| Mupirocin | Mupirocin | 35 | 30 |
| Naproxen | Naproxen | 35 | suppressed |
| Valsartan | Valsartan | 35 | 12 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 17 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 32 | suppressed |
| Loperamide | Loperamide Hcl | 32 | 18 |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Baclofen | Baclofen | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Buprenorphine | Buprenorphine | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Cholestyramine Light | Cholestyramine | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 23 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Colchicine | Colchicine | 24 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Fetzima | Levomilnacipran Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rayaldee | Calcifediol | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,401.81 · 77 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Ambulatory Monitoring & Diagnostics Undivided, Auvelity, BREZTRI, COMIRNATY, CREON, FANAPT, FARXIGA, GEMTESA, IBSRELA, INSPIRE, Kerendia, Korlym, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Symbravo, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error